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tor 2-posAbstract Background: Obesity is a major negative determinant of breast cancer outcome.
However, there are contrasting data on the differential impact of obesity on speciﬁc breast
cancer subtypes. In particular, very little is known on human epidermal growth factor receptor
2-positive (HER2+) tumours.
Patients and methods: We assessed the prognostic role of increased body mass index (BMI) on
a consecutive series of non-metastatic HER2+ patients treated at our institution before the
introduction of adjuvant Trastuzumab. We separately analysed oestrogen receptor-positive
(ER+) and -negative (ER) HER2+ cases.
Results: In ER/HER2+ tumours we observed a signiﬁcantly worse overall survival (Hazard
ratio (HR) 1.79, p-value 0.041) and cumulative incidence of distant metastases (HR 2.03,
p-value 0.019) in obese (BMI > 30) versus normal/underweight (BMI < 25) patients. Local
relapses appeared to be non-signiﬁcantly reduced in obese patients, masking the overall effect
on disease-free survival. Outcome in ER+ tumours, instead, was not signiﬁcantly different
between BMI groups.
Conclusions: Obesity signiﬁcantly correlates with worse overall survival and cumulative inci-
dence of distant metastases in ER/HER2 positive breast cancer. Differences in the biologylsevier Ltd. All rights reserved.
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epidermal growth factor receptor 2-posof breast tumours may determine individual susceptibility to obesity. The biology of the
underlying tumour should be taken into account in the design of dietary intervention trials
in breast cancer.
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Besides its established role as a risk factor, there is
now widespread consensus on the importance of obesity
as a negative prognostic factor for breast cancer.1–3 This
recognition has provided a strong rationale for past and
on-going studies on the metabolic control of breast can-
cer patients through dietary or pharmacological inter-
ventions.4–7
Breast cancer is, however, a biologically heteroge-
neous disease in which treatment modalities are dictated
by molecular features;8 deﬁnitive evidence is still lacking
on the impact of obesity on speciﬁc breast cancer types.
Studies including information on oestrogen receptor
(ER)-positive versus -negative tumours were meta-ana-
lysed by Niraula et al.2 The authors concluded that
the receptor status did not signiﬁcantly alter the obesity
eﬀect on overall survival (OS) (obese/normal hazard
ratio (HR): 1.31 and 1.18 in ER+ and ER, respec-
tively) or on breast cancer-speciﬁc survival (BCSS)
(obese/normal HR: 1.36 and 1.46 in ER+ and ER,
respectively). However, there was substantial heteroge-
neity among the studies included in the analysis, due
to diﬀerences in body mass index (BMI) categorisation
and variability in the deﬁnition of the ER disease, with
early studies considering tumours with <10% ER
expression as ER negative, contrarily to current guide-
lines.8 Individual studies did in fact observe diﬀerences
between ER+ and ER groups.9,10
If diﬀerential eﬀects according to hormone receptor
status are still a matter of debate, even less is known
on human epidermal growth factor receptor 2-positive
(HER2+) tumours. In the present study, we assessed
the prognostic role of increased BMI on a consecutive
series of non-metastatic HER2+ patients treated at
our institution. As the introduction of targeted therapy
has radically altered the natural history of this disease,
we decided to limit our analysis to patients treated
before the introduction of Trastuzumab adjuvant ther-
apy. ER+ and ER HER2+ tumours were separately
analysed, as they constitute clinically and biologically
distinct groups.8,11 Surprisingly, a role for obesity could
be observed only in ER tumours, with a signiﬁcantly
worse OS and an increased risk of distant metastases.2. Patients and methods
We systematically collected information on all con-
secutive breast cancer patients operated at the European
Institute of Oncology in a dedicated data base, thus werella L. et al., Obesity increases the
itive breast cancer patients, Eur Jhad access to the clinical data of interest (from 1995 to
2005, prior to Trastuzumab adjuvant therapy). We iden-
tiﬁed 1250 HER2+ early stage breast cancer patients
operated during this period for whom data were avail-
able regarding weight and height, which we used to cal-
culate the BMI [weight in kilograms/(height in metres)2].
Data were also available regarding age, menopausal
state, date of surgery, tumour characteristics (histologi-
cal type, tumour size, nodal involvement, grade, perivas-
cular inﬁltration, Ki-67 and ER/progesterone receptor
(PgR) expression) and treatment modality (type of sur-
gery, adjuvant radiotherapy, endocrine therapy and
chemotherapy).
Patients’ follow-up included: physical examination
every 6 months, annual mammography and breast ultra-
sound, blood tests every 6–12 months and, in case of
symptoms, further evaluation. When possible, the status
of those women not attending the scheduled follow-up
visits at the institute for more than one year was
obtained by telephone contact. Forty patients (3.2%)
were lost to follow-up. The median length of follow-up
was 8.2 years. The study was approved by the Institu-
tional Review Board.2.1. Statistics
Patients were assigned to BMI groups, according to
the standard World Health Organisation (WHO) cate-
gorisation,12 as follows: underweight (BMI < 18.5), nor-
mal weight (BMI between 18.5 and 24.99), overweight
(BMI between 25 and 29.99) and obese (BMIP 30).
Diﬀerences in the distribution of subject characteris-
tics between groups were evaluated by the Chi-square
test.
End-points included disease-free survival (DFS),
overall survival (OS), cumulative incidence of local or
regional recurrence (CI-LR) and distant metastases
(CI-DM). DFS was deﬁned as the time from surgery
to events such as relapse (including ipsilateral breast
recurrence), appearance of a second primary cancer
(including contralateral breast cancer), or death, which-
ever occurred ﬁrst. OS was deﬁned as the time from sur-
gery until the date of death (from any cause). DFS and
OS functions were estimated using the Kaplan–Meier
method. The log-rank test was used to assess diﬀerences
between groups. The CI-LR and CI-DM were deﬁned as
the time from surgery to the appearance of a local or
regional recurrence and distant metastases, respectively.
CI-LR and CI-DM functions were estimated accord-
ing to methods described by Kalbﬂeisch and Prentice,13incidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
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The Gray’s test was used to assess cumulative incidence
diﬀerences between groups.
The hazard ratios (HRs,) comparing obese patients
versus under/normal weight patients and overweight
patients versus under/normal weight patients, were esti-
mated using a Cox proportional hazards multivariable
model, controlled for age at diagnosis, menopausal sta-
tus, number of positive lymph nodes, tumour size,
grade, percent of oestrogen receptor-positive cells (as a
continuous variable), perivascular invasion and type of
surgery.
In order to investigate the shape of the relationship
between BMI and the hazard of the considered out-
comes, multivariable Cox second-order fractional poly-
nomial models were used.14 Brieﬂy, second-order
fractional polynomial models are a family of models
generated from power transformations of a continuous
exposure variable (in our case BMI), restricted to a
predeﬁned set of exponents (in our case the following
exponents were tested: 2, 1, 0.5, 0, 0.5, 1, 2 and
3). The best ﬁt among the family of models generated
from the combinations of exponents is deﬁned as that
with the lowest residual deviance. The family oﬀers con-
siderably ﬂexibility, since a rich set of possible functions,
including some ‘U-shaped’ and ‘J-shaped’ relations, may
be accommodated.
All analyses were carried out with the SAS software
(SAS Institute, Cary, NC) and the R software (http://
cran.r-project.org/) with the cmprsk package developed
by Gray (http://biowww.dfci.harvard.edu/~gray/). All
reported p-values are two-sided.
3. Results
3.1. Study population
Table 1 lists selected demographic, clinical and path-
ological characteristics and local and systemic treat-
ments of the study population at the time of surgery
(n = 1250), categorised according to oestrogen receptor
(ER) status and WHO BMI classes: normal-under-
weight (BMI < 25), overweight (25 6 BMI < 30) and
obese (BMIP 30). Underweight patients were grouped
together with normal weight as only 53 patients had a
BMI < 18.5.
The prevalence of obese patients in our cohort was
8.1%, in line with the overall prevalence of obesity in
the Italian population.15,16 BMI showed a signiﬁcantly
diﬀerent distribution (p = 0.0032) between the 759
patients with ER positive breast cancer and the 491
patients with ER negative breast cancer (19.5% and
7.8% of overweight and obese patients, respectively, in
the ER positive group and 26.7% and 9.6% of over-
weight and obese patients, respectively, in the ER nega-
tive group).Please cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur JNo signiﬁcant diﬀerences were found in either
group as regards primary tumour size, lymph node
involvement, grade, perivascular invasion or Ki-67
score. Obese and overweight patients were on average
signiﬁcantly older than normal/underweight patients
both in the ER positive (p < 0.001) and ER negative
group (p < 0.001). Accordingly, menopausal status
was signiﬁcantly associated with BMI distribution in
both groups.
Obese and overweight patients were more likely to
have undergone conservative surgery than normal-
underweight patients [83.1%, 75.7% and 67%, respec-
tively, in the ER positive group (p = 0.009), and 66%,
67.9% and 58.5% in the ER negative group
(p = 0.142)]. No signiﬁcant diﬀerences were noted for
adjuvant systemic therapy. However, in the ER positive
group, obese patients were more likely to receive anthra-
cycline-containing chemotherapy (22% versus 12% of
overweight and normal-underweight patients,
p = 0.043). None of the patients received Trastuzumab
in the adjuvant setting.
3.2. Recurrence in ER+/HER2+ tumours
Overall, 246 ﬁrst events were observed among the
759 patients with HER2 positive, ER positive breast
cancer during the follow-up period (Table 2), with
68 local or regional recurrences, 112 distant metastases
and 66 other events (15 contralateral breast cancers,
40 s primaries and 11 deaths from causes other
than breast cancer). 118 patients died during the fol-
low-up.
No signiﬁcant diﬀerences in OS or DFS could be
observed among the three BMI groups. The 5-year OS
proportions were 93.4% (95% conﬁdence interval (CI):
91.0–95.2%) in the under/normal weight patients,
94.6% (95% CI: 89.4–97.2%) in the overweight patients
and 93.2% (95% CI: 82.9–97.4%) in the obese patients
(p-value 0.849) (Fig. 1A).
The 5-year DFS proportions were 74.8% (95% CI:
70.9–78.2%) in the under/normal weight patients,
76.7% (95% CI: 68.9–82.7%) in the overweight patients
and 83.9% (95% CI: 71.2–91.3%) in the obese patients
(p-value 0.554) (Fig. 1B).
We then separated ﬁrst events into local/regional
and distant recurrences and computed the 5-year
cumulative incidences. No local recurrence was
recorded among obese patients. In contrast, an inci-
dence of 4.1% (95% CI: 1.0–9.9%) and 6.9% (95%
CI: 5.0–9.4%) was observed, respectively, in the over-
weight patients and in the under/normal weight
patients; however the diﬀerences between the three
groups were not statistically signiﬁcant (Gray test
p-value 0.273) (Fig. 1C). The 5-year CI-DM was
comparable in the three groups (Gray test p-value
0.725) (Fig. 1D).incidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
Table 1
Baseline characteristics and treatment of patients, by oestrogen receptor status and body mass index (BMI) category.a
Variable ER positive (P1%) ER negative
Under/normal
weight
Overweight Obese Under/normal
weight
Overweight Obese
N = 552 N = 148 N = 59 N = 313 N = 131 N = 47
N (%) N (%) N (%) p* N (%) N (%) N (%) p
Age at surgery <0.001 <0.001
<35 49 (8.9) 4 (2.7) 0 (0) 18 (5.8) 2 (1.5) 0 (0)
35–50 290 (52.5) 40 (27) 19 (32.2) 138 (44.1) 35 (26.7) 11 (23.4)
51–65 175 (31.7) 84 (56.8) 35 (59.3) 124 (39.6) 73 (55.7) 25 (53.2)
>65 38 (6.9) 20 (13.5) 5 (8.5) 33 (10.5) 21 (16) 11 (23.4)
Menopausal status <0.001 <0.001
Premenopausal 325 (58.9) 48 (32.4) 13 (22) 149 (47.6) 32 (24.4) 10 (21.3)
Postmenopausal 227 (41.1) 100 (67.6) 46 (78) 164 (52.4) 99 (75.6) 37 (78.7)
Year of Surgery 0.632 0.890
<1998 4 (0.7) 1 (0.7) 0 (0) 6 (1.9) 2 (1.5) 0 (0)
1998–2001 206 (37.3) 58 (39.2) 17 (28.8) 120 (38.3) 51 (38.9) 17 (36.2)
2002–2005 342 (62) 89 (60.1) 42 (71.2) 187 (59.7) 78 (59.5) 30 (63.8)
Histology 0.829 0.804
Ductal 502 (90.9) 138 (93.2) 52 (88.1) 288 (92) 116 (88.5) 42 (89.4)
Lobular 19 (3.4) 2 (1.4) 2 (3.4) 4 (1.3) 2 (1.5) 1 (2.1)
Mixed 13 (2.4) 4 (2.7) 2 (3.4) 0 (0) 0 (0) 0 (0)
Other 18 (3.3) 4 (2.7) 3 (5.1) 21 (6.7) 13 (9.9) 4 (8.5)
pT 0.382 0.380
pTX 2 (0.4) 0 (0) 1 (1.7) 4 (1.3) 3 (2.3) 2 (4.3)
pT1 314 (56.9) 79 (53.4) 26 (44.1) 175 (55.9) 66 (50.4) 20 (42.6)
pT2 198 (35.9) 60 (40.5) 29 (49.2) 113 (36.1) 47 (35.9) 20 (42.6)
pT3 32 (5.8) 8 (5.4) 3 (5.1) 17 (5.4) 14 (10.7) 4 (8.5)
pT4 6 (1.1) 1 (0.7) 0 (0) 4 (1.3) 1 (0.8) 1 (2.1)
Positive lymph nodes 0.728 0.696
Unknown 11 (2) 4 (2.7) 0 (0) 5 (1.6) 2 (1.5) 0 (0)
None 283 (51.3) 67 (45.3) 31 (52.5) 159 (50.8) 63 (48.1) 18 (38.3)
1–3 159 (28.8) 49 (33.1) 19 (32.2) 71 (22.7) 32 (24.4) 13 (27.7)
4+ 99 (17.9) 28 (18.9) 9 (15.3) 78 (24.9) 34 (26) 16 (34)
Grade 0.311 0.888
Unknown 13 (2.4) 1 (0.7) 3 (5.1) 14 (4.5) 4 (3.1) 1 (2.1)
1–2 240 (43.5) 65 (43.9) 19 (32.2) 61 (19.5) 26 (19.8) 8 (17)
3 299 (54.2) 82 (55.4) 37 (62.7) 238 (76) 101 (77.1) 38 (80.9)
PVI 0.480 0.471
Unknown 1 (0.2) 0 (0) 1 (1.7) 3 (1) 2 (1.5) 2 (4.3)
Absent 335 (60.7) 94 (63.5) 43 (72.9) 204 (65.2) 81 (61.8) 27 (57.4)
Present 28 (5.1) 5 (3.4) 2 (3.4) 6 (1.9) 3 (2.3) 1 (2.1)
Focal 96 (17.4) 27 (18.2) 5 (8.5) 36 (11.5) 24 (18.3) 9 (19.1)
Diﬀuse 92 (16.7) 22 (14.9) 8 (13.6) 64 (20.4) 21 (16) 8 (17)
PgR 0.428 0.621
Unknown 0 (0) 0 (0) 0 (0) 1 (0.3) 0 (0) 0 (0)
PgR = 0 160 (29) 46 (31.1) 13 (22) 306 (97.8) 129 (98.5) 47 (100)
PgR > 0 392 (71) 102 (68.9) 46 (78) 6 (1.9) 2 (1.5) 0 (0)
Ki-67 0.581 0.407
Unknown 2 (0.4) 0 (0) 1 (1.7) 7 (2.2) 4 (3.1) 2 (4.3)
<14% 48 (8.7) 17 (11.5) 5 (8.5) 11 (3.5) 3 (2.3) 3 (6.4)
P14% 502 (90.9) 131 (88.5) 53 (89.8) 295 (94.2) 124 (94.7) 42 (89.4)
Surgery 0.009 0.142
Conservative 370 (67) 112 (75.7) 49 (83.1) 183 (58.5) 89 (67.9) 31 (66)
Mastectomy 182 (33) 36 (24.3) 10 (16.9) 130 (41.5) 42 (32.1) 16 (34)
Radiotherapy 0.515 0.542
Unknown 14 (2.5) 7 (4.7) 1 (1.7) 7 (2.2) 7 (5.3) 5 (10.6)
No 108 (19.6) 28 (18.9) 8 (13.6) 92 (29.4) 31 (23.7) 11 (23.4)
Yes 430 (77.9) 113 (76.4) 50 (84.7) 214 (68.4) 93 (71) 31 (66)
(continued on next page)
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Table 1 (continued )
Variable ER positive (P1%) ER negative
Under/normal
weight
Overweight Obese Under/normal
weight
Overweight Obese
N = 552 N = 148 N = 59 N = 313 N = 131 N = 47
N (%) N (%) N (%) p* N (%) N (%) N (%) p
Adjuvant treatment 0.846 0.963
Nil 15 (2.7) 4 (2.7) 1 (1.7) 54 (17.3) 23 (17.6) 6 (12.8)
Hormonotherapy 157 (28.4) 48 (32.4) 21 (35.6) 1 (0.3) 0 (0) 0 (0)
Chemotherapy 20 (3.6) 6 (4.1) 1 (1.7) 243 (77.6) 103 (78.6) 39 (83)
Chemotherapy and
hormonotherapy
360 (65.2) 90 (60.8) 36 (61) 15 (4.8) 5 (3.8) 2 (4.3)
Anthracycline-containing
regimen$
0.043 0.945
Yes 305 (82.1) 75 (81.1) 24 (65.0) 190 (75.0) 78 (76.0) 30 (73.0)
No 67 (18.0) 18 (19.0) 13 (35.0) 65 (25.0) 25 (24.0) 11 (27.0)
Abbreviations: ER, oestrogen receptors; PgR, progesterone receptors; PVI, peritumoural vascular invasion.
a Under/normal weight: BMI < 25; overweight: 25 6 BMI < 30; obese: BMIP 30.
* Chi-square test comparing proportions between BMI categories. p-Value were calculated excluding unknown values.
$ Evaluated only in patients receiving adjuvant chemotherapy.
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Overall, 194 ﬁrst events were observed among the 491
patients with HER2 positive, ER negative breast cancer
during the follow-up period (Table 2), with 52 local or
regional recurrences, 104 distant metastases and 38
other events (10 contralateral breast cancers, 14 s prima-
ries and 14 deaths from causes other than breast cancer).
122 patients died during the follow-up.
Within this group of patients, outcome diﬀerences
between obese patients and the remaining BMI groups
were more pronounced. The 5-year OS proportions were
85.9% (95% CI: 81.6–89.3%) in the under/normal weight
patients, 82.4% (95% CI: 74.7–87.9%) in the overweight
patients, and 73.5% (95% CI: 58.1–84.0%) in the obese
patients (p-value 0.041) (Fig. 2A).
The 5-year DFS proportions were 69.1% (95% CI:
63.6–73.9%) in the under/normal weight patients,
68.1% (95% CI: 59.3–75.4%) in the overweight patients
and 55.2% (95% CI: 39.6–68.4%) in the obese patients
(p-value 0.170) (Fig. 2B).
Separate analysis of local/regional and distant recur-
rences revealed a higher 5-year CI-DM in obese patients
(33.4%, 95% CI: 22.1–50.5%) than in overweight (17.9%,Table 2
Observed events, by oestrogen receptor status and body mass index (BMI)
Variable Oestrogen receptor-positive (ER+) (P1%)
Under/normal weight Overweight
N = 552 N = 148
N (%) N (%)
Observed ﬁrst event 184 (33.3) 47 (31.8)
Local and regional event 54 (9.8) 12 (8.1)
Distant metastases 85 (15.4) 20 (13.5)
Other eventsb 45 (8.2) 15 (10.1)
Total observed deaths 87 (15.8) 21 (14.2)
a Under/normal weight: BMI < 25; overweight: 25 6 BMI < 30; obese: B
b Including death as ﬁrst event.
Please cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur J95% CI: 12.3–25.9%) and under/normal weight patients
(17.5%, 95% CI: 13.8–22.4%). The Gray test p-value was
0.019 (Fig. 2D).
Similar to ER+/HER2+ patients, we observed fewer
local recurrences in obese patients, with a 5-year CI-LR
of 2.3% (95% CI: 0.3–16.0%) versus 7.8% (95% CI: 4.3–
14.1%) in the overweight and 10.4% (95% CI: 7.5–
14.5%) in the under/normal weight patients. However,
the diﬀerences between the three groups were not statis-
tically signiﬁcant (Gray test p-value 0.205) (Fig. 2C).
The multivariable analyses (table 3) conﬁrmed the
results observed in the univariate analysis: the adjusted
risk of death and distant metastases were signiﬁcantly
higher in the obese patients than in the under/normal
weight patients (HR for death: 1.79, 95% CI: 1.03–
3.10; HR for distant metastases: 2.03, 95% CI: 1.13–
3.63), whereas the risk of local/regional events was lower,
albeit not statistically signiﬁcant (adjusted obese versus
under/normal weight HR: 0.37, 95% CI: 0.09–1.55).3.4. BMI as a continuous variable
We sought to better characterise the strong associa-
tion we observed between obesity and distant metastasescategorya.
ER negative (ER)
Obese Under/normal weight Overweight Obese
N = 59 N = 313 N = 131 N = 47
N (%) N (%) N (%) N (%)
15 (25.4) 121 (38.7) 49 (37.4) 24 (51.1)
2 (3.4) 38 (12.1) 12 (9.2) 2 (4.3)
7 (11.9) 62 (19.8) 25 (19.1) 17 (36.2)
6 (10.2) 21 (6.7) 12 (9.2) 5 (10.6)
10 (16.9) 71 (22.7) 33 (25.2) 18 (38.3)
MIP 30.
incidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
Fig. 1. Overall survival (panel A), disease-free survival (panel B), cumulative incidence of local and regional (LR) recurrence (panel C) and
cumulative incidence of distant metastasis (DM) (Panel D), for the 759 patients with oestrogen receptor-positive (ER+)/human epidermal growth
factor receptor 2-positive (HER2+) breast cancer, by body mass index category. Univariate log-rank and Gray test p-values and hazard ratios
(HRs) adjusted for age, pT, Grade, ER, pN, Menopause, peritumoural vascular invasion (PVI), Surgery, are reported.
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able, using second-order multivariable fractional poly-
nomial models (Fig. 3).
The relationship between BMI and HR appeared as a
U-shaped curve, increasing non-linearly both at high
and low BMI values. When we computed the point-wise
95% conﬁdence intervals, the right branch of the curve
became signiﬁcant (lower HR CI bound >1.00) at a
BMI value of approximately 27.5 (HR: 1.18, 95% CI:
1.01–1.37, when compared with the median BMI value
of 24.2), after which the HR continued to grow expo-
nentially with the BMI; on the left side, because of the
small number of underweight patients, 95% CIs were
much wider and included the 1.00 threshold at any
value. The fractional polynomial model ﬁt the dataPlease cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur Jsigniﬁcantly better than the conventional linear model
(p = 0.042). Similar analyses with BMI as a continuous
variable did not show signiﬁcant results either in ER+
tumours, or when we studied DFS or the incidence of
local events (not shown).4. Discussion
Little information is available on the impact of BMI
on outcome in HER2+ breast cancer.
In this study, we have examined a consecutive series
of 1250 patients treated at our institution before 2006,
prior to the introduction of adjuvant Trastuzumab. This
time frame was chosen in order to provide long term
follow-up information and to minimise any potentialincidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
Fig. 2. Overall survival (panel A), disease-free survival (panel B), cumulative incidence of local and regional (LR) recurrence (panel C) and
cumulative incidence of distant metastasis (DM) (Panel D), for the 491 patients with oestrogen receptor-negative (ER)/HER2 breast cancer, by
body mass index category. Univariate log-rank and Gray test p-values and hazard ratios (HRs) adjusted for age, pT, Grade, pN, Menopause,
peritumoural vascular invasion (PVI), Surgery, are reported.
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ment, as the introduction of Trastuzumab radically
altered the natural history of this disease. Ongoing ret-
rospective analyses within the Herceptin Adjuvant
HERA and the North American Breast Cancer Group
trials, for which this study may provide a historical com-
parison, will address the issue of whether BMI is a pre-
dictive factor for patients’ response to adjuvant
Trastuzumab therapy.
We used the standard WHO BMI categorisation
and included our small number of underweight cases
into the normal weight group. We stratiﬁed patients
according to oestrogen receptor status, as this separates
two clinically and biologically distinct groups of
HER2+ patients.8,11Please cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur JThe main ﬁnding of our study is that, within HER2+
tumours, lack of oestrogen receptor expression separates
patients in which obesity correlates with worse outcome
from those in which it does not: only ER obese
patients had a signiﬁcantly worse overall survival com-
pared with underweight/normal or overweight patients
(HR of 1.79). In the same group the HR for DFS was
1.34 but did not reach statistical signiﬁcance. However,
the number of distant metastases was more than double
in obese patients (HR 2.03, p-value 0.019), whereas local
recurrence showed a slightly lower, albeit not signiﬁcant,
incidence. This pattern is in agreement with previous
data on a large unsorted population,3 and suggests that
an apparently modest eﬀect on combined outcome
parameters (such as DFS) may be due to the contrastingincidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
Table 3
Multivariate analysis, by oestrogen receptor status.
Overall survival (OS) Disease-free survival
(DFS)
Local and regional
(LR)
Distant metastasis (DM)
Hazard ratio (HR)
(95% conﬁdence
interval (CI))
p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Oestrogen receptor-positive (ER+) group
Body mass
index
(BMI)
Obese versus
under/normal
weight
1.05 (0.53; 2.09) 0.91 0.75 (0.43; 1.31) 0.31 0.38 (0.09; 1.57) 0.18 0.81 (0.36; 1.84) 0.62
Overweight
versus under/
normal weight
0.77 (0.46; 1.26) 0.29 0.88 (0.63; 1.23) 0.45 0.82 (0.43; 1.58) 0.54 0.90 (0.54; 1.50) 0.68
Menopausal
status
Pre versus post 1.10 (0.62; 1.95) 0.76 0.99 (0.67; 1.48) 0.97 0.99 (0.45; 2.16) 0.97 0.89 (0.50; 1.60) 0.70
pT 2/3/4 versus 1 1.35 (0.89; 2.06) 0.16 1.31 (0.99; 1.74) 0.06 0.90 (0.52; 1.54) 0.69 1.61 (1.04; 2.48) 0.03
Positive
lymph
nodes (LN)
1–3 versus
none
1.30 (0.79; 2.13) 0.30 0.96 (0.69; 1.34) 0.82 0.80 (0.44; 1.46) 0.47 1.31 (0.78; 2.20) 0.31
4+ versus none 2.85 (1.74; 4.68) <0.001 2.10 (1.50; 2.95) <0.001 1.06 (0.53; 2.13) 0.86 3.37 (2.01; 5.65) <0.001
Grade 1–2 versus 3 0.58 (0.38; 0.86) 0.01 0.80 (0.61; 1.05) 0.10 0.69 (0.42; 1.15) 0.15 0.69 (0.46; 1.04) 0.08
Peritumoural
vascular
invasion
(PVI)
Present versus
absent
1.20 (0.78; 1.83) 0.41 1.28 (0.95; 1.71) 0.10 1.6 (0.94; 2.73) 0.08 1.09 (0.70; 1.69) 0.71
Surgery Conservative
versus
mastectomy
0.72 (0.47; 1.09) 0.12 0.84 (0.63; 1.11) 0.22 1.0 (0.57; 1.74) 0.99 0.66 (0.43; 0.99) 0.05
Age +10 years
increase
1.32 (1.03; 1.69) 0.03 1.09 (0.91; 1.29) 0.36 1.0 (0.71; 1.42) 1.00 0.95 (0.74; 1.23) 0.72
ER negative (ER) group
BMI Obese versus
under/normal
weight
1.79 (1.03; 3.10) 0.04 1.34 (0.84; 2.13) 0.22 0.37 (0.09; 1.55) 0.17 2.03 (1.13; 3.63) 0.02
Overweight
versus under/
normal weight
1.16 (0.75; 1.79) 0.50 0.99 (0.70; 1.39) 0.94 0.77 (0.40; 1.51) 0.45 1.07 (0.66; 1.74) 0.78
Menopausal
status
Pre versus post 1.13 (0.63; 2.05) 0.68 1.00 (0.63; 1.60) 0.99 2.05 (0.84; 5.02) 0.12 0.74 (0.39; 1.42) 0.37
pT 2/3/4 versus 1 1.57 (1.04; 2.36) 0.03 1.53 (1.11; 2.10) 0.01 1.21 (0.66; 2.23) 0.54 1.62 (1.04; 2.53) 0.03
Positive LN 1–3 versus
none
1.73 (1.02; 2.91) 0.04 1.68 (1.14; 2.48) 0.01 1.07 (0.50; 2.32) 0.86 2.62 (1.48; 4.64) <0.001
4+ versus none 2.53 (1.52; 4.21) <0.001 2.75 (1.86; 4.07) <0.0001 2.26 (1.09; 4.69) 0.03 4.04 (2.27; 7.20) <0.001
Grade 1–2 versus 3 0.58 (0.32; 1.04) 0.07 0.91 (0.63; 1.32) 0.62 1.11 (0.57; 2.16) 0.77 0.64 (0.36; 1.16) 0.14
PVI Present versus
absent
1.87 (1.21; 2.88) <0.001 1.22 (0.87; 1.71) 0.24 0.83 (0.41; 1.67) 0.60 1.52 (0.96; 2.39) 0.07
Surgery Conservative
versus
mastectomy
1.11 (0.75; 1.64) 0.60 1.45 (1.05; 1.98) 0.02 2.26 (1.15; 4.41) 0.02 1.19 (0.78; 1.82) 0.41
Age +10 years
increase
1.02 (0.78; 1.32) 0.91 0.92 (0.75; 1.14) 0.45 1.28 (0.87; 1.90) 0.21 0.72 (0.53; 0.97) 0.03
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Treating BMI as a continuous variable showed a typical
U-shaped correlation with distant metastases, consistent
with what observed in previous BMI-cancer mortality
studies.17 Thus, categorising patients according to the
standard WHO classiﬁcation,12 which is based on cutoﬀ
points arbitrarily derived from heterogeneous BMI asso-
ciation studies, may inaccurately reﬂect the continuous
relationship between BMI and cancer outcome
variables.Please cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur JAs a whole, outcome was not signiﬁcantly diﬀerent
between BMI classes in HER2+ tumours, in agreement
with the only other study, to date, that separately eval-
uated HER2+ tumours.18 No signiﬁcant diﬀerences
could be identiﬁed within the ER+/HER2+ group. This
is consistent with recent data showing that adjuvant
endocrine therapy is less eﬀective in obese patients, but
only when aromatase inhibitors are used, whereas mini-
mal or no diﬀerences are noticed with Tamoxifen.19,20
Although we do not have detailed information on theincidence of distant metastases in oestrogen receptor-negative human
Cancer (2013), http://dx.doi.org/10.1016/j.ejca.2013.07.016
Fig. 3. Relationship between body mass index (BMI), on a continuous
scale, and the hazard of distant metastases, in patients with HER2
positive and oestrogen receptor (ER)-negative breast cancer. The
relationship is modelled by multivariable fractional polynomials (bold
line). Model-based 95% CIs are also reported (dashed lines). The
median BMI value (24.2) was considered as the reference value in the
estimation of the hazard ratio. Estimates were adjusted for age, pT,
Grade, pN, Menopause, peritumoural vascular invasion (PVI),
Surgery in a Cox proportional hazard model. The rug plots placed
at the top and bottom of the graph show the BMI values in patients
that relapsed (top) and in those who did not (bottom).
L. Mazzarella et al. / European Journal of Cancer xxx (2013) xxx–xxx 9type of endocrine therapy in our population, given the
time window of our analysis it is likely that the vast
majority of our patients received Tamoxifen as
adjuvant.
Our study has a number of strengths: long median
follow-up (8.2 years); detailed treatment history; direct
measurement of BMI variables; availability of patient-
level data, as opposed to study-level data, which reduces
the risk of selection bias and provides results which are
closer to everyday clinical practice. Weaknesses are the
absence of information on treatment dosage, the retro-
spective nature of the analysis and the relatively small
number of obese patients (8.1%) in the cohort. Such
small prevalence of obesity is in line with the general
prevalence in Italy at the time,15 which has only margin-
ally increased in the more recent years and it is signiﬁ-
cantly smaller than in other Western Countries.16
In theory, the poorer outcome of ER/HER2+
obese patients can be explained by diﬀerences in treat-
ment administration and/or biological susceptibility to
obesity. Although we do not have information on sys-
temic therapy dosing, treatment variables seem unlikely
candidates as: (i) there was no signiﬁcant diﬀerence in
the percentage of patients receiving chemotherapy
between BMI classes; (ii) the relatively higher frequencyPlease cite this article in press as: Mazzarella L. et al., Obesity increases the
epidermal growth factor receptor 2-positive breast cancer patients, Eur Jof conservative surgery in obese patients, which is the
most evident treatment diﬀerence, should more proba-
bly aﬀect local recurrence than distant metastases, and
this is not the case in our study and (iii) there was no
eﬀect in ER+ tumours, which served as a control group
in this respect.
We favour a model in which the biology of ER/
HER2+ tumoursmakes themmore prone tometastasisa-
tion in response to systemic metabolic alterations. Oest-
rogen, often invoked as the main mediator of obesity-
related progression in breast cancer, does not seem to play
a role in this case. Instead, the pattern of relapse described
here would suggest an interaction with pathways impli-
cated in metastasis. On a speculative note, one likely can-
didate in this sense may be the Transforming Growth
Factor beta (TGFb) pathway, as suggested by preclinical
data showing that (i) increased TGFb levels favour
metastases in a mouse model of ER/HER2+ spontane-
ous tumourigenesis21 which responds to high fat diet22
and (ii) TGFb plays a crucial role in systemic metabolic
control, indeed its circulating levels are dramatically
increased in diet-induced or genetic models of obesity.23
Other mechanisms can also be implicated, such as angio-
genesis21 and inﬂammatory cytokine imbalance,24 both of
which are perturbed in obese organisms.25,26
Our results highlight the importance of the underly-
ing tumour biology in evaluating BMI as a prognostic
factor in breast cancer. This may have important conse-
quences for the interpretation and design of dietary
intervention trials. For instance, in the Women’s Inter-
vention Nutrition Study (WINS), the positive eﬀects of
dietary fat reduction on outcome were more evident in
ER tumours,4 in agreement with our hypothesis that
lack of an oestrogen receptor identiﬁes tumours inher-
ently more susceptible to systemic metabolism. How-
ever, in the WINS, outcome diﬀerences did not reach
statistical signiﬁcance. Stratiﬁcation for HER2 and ER
status could help improve the identiﬁcation of patients
whose cancer prognosis can beneﬁt from weight loss.
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